ライフサイエンスコーパス: promyelocytic leukaemia

1 h high-risk and low-risk patients with acute promyelocytic leukaemia.

2 de (ATO), are by and large curative in acute promyelocytic leukaemia(3), but whether 'differentiation

3 c acid (RA)-induced differentiation of acute promyelocytic leukaemia and HL-60 cells, CD38 is one of

4 s and co-repressors contribute towards acute promyelocytic leukaemia and thyroid hormone resistance s

5 c leukaemia (PML) tumour suppressor of acute promyelocytic leukaemia (APL) accumulates in the PML nuc

6 Acute promyelocytic leukaemia (APL) arises following a recipro

7 or some cancer types, such as treating acute promyelocytic leukaemia (APL) by retinoic acid.

8 t of all-trans-retinoic acid resistant acute promyelocytic leukaemia (APL) cases, encodes a DNA bindi

9 ranulocytic differentiation of the NB4 acute promyelocytic leukaemia (APL) cell line, using two diffe

10 The PML gene of acute promyelocytic leukaemia (APL) encodes a cell growth and

11 Acute promyelocytic leukaemia (APL), associated with chromosom

12 Here we show that, in acute promyelocytic leukaemia (APL), ILC2s are increased and h

13 discovered in patients suffering from acute promyelocytic leukaemia (APL).

14 de a new model for the pathogenesis of acute promyelocytic leukaemia (APL).

15 cus, are oncogenic and result in human acute promyelocytic leukaemia (APL).

16 for acute myeloid leukaemia (excluding acute promyelocytic leukaemia) compared with chemotherapy alon

17 gible patients (aged >/=16 years) with acute promyelocytic leukaemia, confirmed by the presence of th

18 previously unknown role for the cytoplasmic promyelocytic leukaemia (cPML) tumour suppressor in TGF-

19 The outlook for patients with acute promyelocytic leukaemia has improved vastly with the use

20 (CBMNCyt) assay conducted with respectively, promyelocytic leukaemia (HL-60) and colon adenocarcinoma

21 myelomonocytic leukaemia (WEHI-3) and Human promyelocytic leukaemia (HL-60) cell lines.

22 d that PTEN is aberrantly localized in acute promyelocytic leukaemia, in which PML function is disrup

23 Acute promyelocytic leukaemia is a chemotherapy-sensitive subg

24 omal translocations with either the PML (for promyelocytic leukaemia) or the PLZF (for promyelocytic

25 r discrete nuclear structures known as ND10, promyelocytic leukaemia (PML) bodies or PODs.

26 Furthermore, the cytoplasmic localization of promyelocytic leukaemia (PML) is mediated by its nuclear

27 SnoN interacts with the promyelocytic leukaemia (PML) protein and is recruited t

28 f SnoN results from its interaction with the promyelocytic leukaemia (PML) protein and the accumulati

29 The promyelocytic leukaemia (PML) protein controls multiple

30 Expression of TAp73beta efficiently induced promyelocytic leukaemia (PML) protein expression and PML

31 Here, we show that the tumour suppressor promyelocytic leukaemia (PML) protein is a circadian clo

32 Loss of the promyelocytic leukaemia (PML) tumour suppressor has been

33 The promyelocytic leukaemia (PML) tumour suppressor of acute

34 signatures, including the linear form of the promyelocytic leukaemia (PML)-defined structure in iPSCs

35 Here we show that functional promyelocytic leukaemia protein (PML) nuclear bodies co-

36 Here we present data indicating that (i) the promyelocytic leukaemia protein (PML) physically interac

37 Here we define the critical role of the promyelocytic leukaemia protein (PML) tumour suppressor

38 nuclear matrix-associated domain containing promyelocytic leukaemia protein.

39 We excluded those with acute promyelocytic leukaemia, those seen only for a one-time

40 Here the authors show that, in acute promyelocytic leukaemia, tumour-activated ILC2s secrete

41 target of differentiation therapy for acute promyelocytic leukaemia, wherein retinoic acid dissociat

42 n low-risk and high-risk patients with acute promyelocytic leukaemia, with a high cure rate and less

43 The promyelocytic leukaemia zinc finger (Plzf) protein (enco

44 Here we report that promyelocytic leukaemia zinc finger (PLZF), the BTB-zinc

45 istinct lineage that originates from a novel promyelocytic leukaemia zinc finger (PLZF)-expressing IL

46 or promyelocytic leukaemia) or the PLZF (for promyelocytic leukaemia zinc finger) locus, are oncogeni

47 Gli3 (GLI-Kruppel family member 3) and Plzf (promyelocytic leukaemia zinc finger, also known as Zbtb1